In reply: We appreciate the comments of Pantanowitz et al regarding our paper on the utility of the detection of HHV-8 LNA-1 by immunohistochemistry in the diagnosis of Kaposi's sarcoma.
1
They appear to be concerned because (1) the prevalence of HHV-8 is low in Cleveland, OH but high in other areas and that we did not report serologic data on our patients, and (2) that HHV-8 can be detected by molecular methods in nonKaposi's sarcoma lesions from patients who harbor HHV-8.
It is true that we did not report the HHV-8 serologic status of patients in our study and that we conducted our study in Cleveland where the prevalence of HHV-8 is likely to be low. Indeed, the seroprevalence of HHV-8 in the United States population as a whole is estimated at 3.5%, 2 much lower than in many high-prevalence African countries. 3 Since our study was a retrospective study, we did not have serological data on our patients. Our manuscript showed that HHV-8 can be detected in tumor cells of virtually all cases of Kaposi's sarcoma. Others have shown similar results, including in endemic Kaposi's sarcoma. [4] [5] [6] None of these studies reported HHV-8 serologic data. While this information would be useful, we believe it does not significantly detract from our overall conclusion that immunohistochemical demonstration of HHV-8 virus in tumor cells of vascular and spindle cell lesions is a useful tool (in association with histopathologic and clinical features) when the diagnosis of Kaposi's sarcoma seems reasonable. We do not advocate diagnosis of Kaposi's sarcoma based on presence of the virus alone due to the possibility of finding HHV-8 in other types of lesions, a view shared by other investigators. 4, 5 As to the second point, we agree with Pantanowitz et al that molecular methods can detect HHV-8 in non-Kaposi's sarcoma lesions. However, PCR-based detection methods for HHV-8 are very sensitive and can produce positive results due to the presence of 'bystander' virus contamination. Previous studies have found HHV-8 sequences by PCR in peripheral blood mononuclear cells in HIV-infected and uninfected patients with Kaposi's sarcoma, 7 and in a healthy blood donor. 8 We and other investigators agree that the presence of such bystander cells was probably responsible for the few series that describe HHV-8 in AS. 4, 5, 9 In the AS study cited by Pantanowitz et al, no histopathological description, photomicrographs, or viral cellular localization of the analyzed cases of Kaposi's sarcoma were included. 10 Importantly, the findings of that study have not been validated by other investigators in a larger series. 9 Finally, Kazakov and colleagues (as cited by Pantanowitz) reported HHV-8 positivity by PCR in a case of multiple eruptive dermatofibromas in an HIV-negative patient. However, in situ hybridization failed to localize HHV-8 to tumor cells. They correctly concluded that the PCR positivity was probably due to blood-born viremia and/or contamination by HHV-8-infected monocytes and lymphyocytes. 11 These observations demonstrate that cellular localization of HHV-8 by immunohistochemistry is more useful for routine diagnostic purposes than standard PCR amplification-based methods.
In conclusion, the use of HHV-8 immunohistochemistry is a very useful tool that, in conjunction with other clinical, morphologic, and phenotypic features, should enable the practicing surgical pathologist to arrive at the correct diagnosis. We do not suggest that HHV-8 immunohistochemistry be used as a stand-alone test in which a positive result equates to a diagnosis of Kaposi's sarcoma. 
